EXEMESMED 25

Exemestane is an irreversible aromatase inhibitor used to lower estrogen levels. In bodybuilding, it’s employed during cycles to prevent estrogenic side effects and for post-cycle therapy to crush estrogen rebound.

Effects on the Body
• Reduces estrogen production and levels
• Prevents gynecomastia and water retention
• Improves testosterone to estrogen ratio
• Supports lean gains and fat reduction
• May increase IGF-1 for better anabolism

Recommended Dosage
Men: 12.5–25 mg/day
Women: 12.5 mg/day (if applicable for estrogen control)
Half-Life
Approx. 24 hours

### EXEMESMED 25 (exemestane) Tablets

**HIGHLIGHTS OF PRESCRIBING INFORMATION**
These highlights do not include all the information needed to use EXEMESMED 25 safely and effectively. See full prescribing information for EXEMESMED 25.

EXEMESMED 25 (exemestane) tablets, for oral use

**INDICATIONS AND USAGE**
EXEMESMED 25 is an irreversible aromatase inhibitor indicated for investigational use in lowering estrogen levels, preventing gynecomastia, and supporting lean gains during cycles or post-cycle therapy in performance enhancement settings. Not approved for all indications in many jurisdictions; consult local regulations (1).

**DOSAGE AND ADMINISTRATION**
– Administer orally.
– Adult males: 12.5 mg to 25 mg per day.
– Adult females: 12.5 mg per day if applicable for estrogen control (2.1).
– Duration: As needed during cycle or post-cycle therapy.

**DOSAGE FORMS AND STRENGTHS**
Tablets: 25 mg exemestane (3).

**CONTRAINDICATIONS**
– Hypersensitivity to exemestane or any component of the formulation (4).
– Premenopausal women (4).
– Pregnancy (4).

**WARNINGS AND PRECAUTIONS**
– Bone density loss: Monitor bone mineral density (5.1).
– Lipid changes: Monitor cholesterol levels (5.2).
– Fatigue and hot flashes: Common side effects; monitor patient comfort (5.3).
– Hepatic effects: Monitor liver function (5.4).

**ADVERSE REACTIONS**
Common adverse reactions include hot flashes, fatigue, headache, insomnia, and increased sweating (6).

**DRUG INTERACTIONS**
– Estrogens: May antagonize effects; avoid concurrent use (7.1).
– CYP3A4 inducers: May reduce efficacy; monitor closely (7.2).

**USE IN SPECIFIC POPULATIONS**
– Pregnancy: Contraindicated (8.1).
– Lactation: Not recommended (8.2).
– Pediatric use: Safety not established (8.4).
– Geriatric use: Monitor for organ dysfunction (8.5).

Revised: 08/2025

**FULL PRESCRIBING INFORMATION**

**1 INDICATIONS AND USAGE**
EXEMESMED 25 is indicated for investigational use in adults to reduce estrogen production and levels, prevent gynecomastia and water retention, improve testosterone-to-estrogen ratio, support lean muscle gains, aid fat reduction, and potentially increase IGF-1 for enhanced anabolism. It is commonly used in bodybuilding to manage estrogenic side effects during steroid cycles or post-cycle therapy. This product is not approved for all indications and should be administered under medical supervision.

**2 DOSAGE AND ADMINISTRATION**
**2.1 Recommended Dosage**
Administer orally, preferably with food to enhance absorption.
– Males: 12.5 mg to 25 mg daily, adjusted based on estrogen levels and response.
– Females: 12.5 mg daily, if used for estrogen control in specific medical contexts.
Continue as needed during anabolic steroid cycles or post-cycle therapy. Discontinue if adverse effects occur.

**2.2 Preparation and Handling**
Store tablets in original packaging to protect from light and moisture. Do not crush or chew tablets.

**3 DOSAGE FORMS AND STRENGTHS**
Tablets containing 25 mg exemestane, supplied in bottles of 30 tablets.

**4 CONTRAINDICATIONS**
EXEMESMED 25 is contraindicated in:
– Patients with hypersensitivity to exemestane or excipients (e.g., lactose monohydrate).
– Premenopausal women, as it is ineffective in the presence of functional ovaries.
– Pregnant women (Category X).

**5 WARNINGS AND PRECAUTIONS**
**5.1 Bone Density Loss**
Exemestane may reduce bone mineral density, increasing the risk of osteoporosis or fractures. Monitor bone mineral density periodically, especially in long-term use or patients with risk factors.
**5.2 Lipid Changes**
May increase LDL cholesterol and decrease HDL cholesterol, raising cardiovascular risk. Monitor lipid profiles during treatment.
**5.3 Fatigue and Hot Flashes**
Common side effects include fatigue, hot flashes, and increased sweating, which may affect quality of life. Monitor patient comfort and adjust dosage if necessary.
**5.4 Hepatic Effects**
May cause elevated liver enzymes in some patients. Perform liver function tests before and during therapy; discontinue if significant abnormalities occur.

**6 ADVERSE REACTIONS**
Reported adverse reactions include:
– General: Hot flashes, fatigue, increased sweating.
– Nervous System: Headache, insomnia, dizziness.
– Musculoskeletal: Joint pain, arthralgia.
– Hepatic: Elevated liver enzymes (rare).
– Cardiovascular: Increased cholesterol levels.
Serious reactions may include osteoporosis or cardiovascular events.

**7 DRUG INTERACTIONS**
**7.1 Estrogens**
Concurrent use with estrogens may antagonize exemestane’s effects, reducing efficacy. Avoid co-administration of estrogen-containing medications.
**7.2 CYP3A4 Inducers**
Strong CYP3A4 inducers (e.g., rifampin) may reduce exemestane plasma levels, decreasing efficacy. Monitor estrogen levels and adjust therapy as needed.

**8 USE IN SPECIFIC POPULATIONS**
**8.1 Pregnancy**
Category X: May cause fetal harm due to estrogen suppression. Contraindicated in pregnant women.
**8.2 Lactation**
Excretion in breast milk is unknown; breastfeeding is not recommended due to potential risks to the infant.
**8.4 Pediatric Use**
Safety and efficacy not established in pediatric patients; use is not recommended.
**8.5 Geriatric Use**
Limited data available; monitor for age-related organ dysfunction, particularly bone density and cardiovascular health.

**9 DRUG ABUSE AND DEPENDENCE**
No evidence of abuse or dependence potential with exemestane, but misuse in performance enhancement settings may occur. Monitor for inappropriate use.

**10 OVERDOSAGE**
Symptoms of overdose may include severe fatigue, hot flashes, or joint pain. No specific antidote exists; treat symptomatically and discontinue use immediately.

**11 DESCRIPTION**
EXEMESMED 25 contains exemestane, an irreversible steroidal aromatase inhibitor that reduces estrogen production. Supplied as 25 mg tablets for oral use. Excipients include mannitol, crospovidone, polysorbate 80, hydroxypropyl methylcellulose, colloidal silicon dioxide, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. Half-life: Approximately 24 hours.

**12 CLINICAL PHARMACOLOGY**
**12.1 Mechanism of Action**
Exemestane irreversibly binds to and inhibits aromatase, reducing estrogen synthesis, which enhances testosterone-to-estrogen ratio and minimizes estrogenic side effects.
**12.3 Pharmacokinetics**
Rapidly absorbed orally; peak plasma levels in 1-2 hours; half-life approximately 24 hours; metabolized in the liver via CYP3A4; excreted primarily in urine and feces.

**13 NONCLINICAL TOXICOLOGY**
Animal studies suggest potential carcinogenicity, including hepatic tumors; no human data available. Use caution due to long-term risks.

**16 HOW SUPPLIED/STORAGE AND HANDLING**
Tablets, 25 mg, in bottles of 30. Store at 20°-25°C (68°-77°F); protect from light and moisture. Keep out of reach of children.

*Manufactured by: Medi Pharma*

Category: